Hyperoxaluria: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | |||
{{CMG}} | |||
{{Infobox Disease | | |||
Name = Hyperoxaluria | | Name = Hyperoxaluria | | ||
Image = | | Image = Oxalate-ion-2D-skeletal.png | | ||
Caption = | | Caption = [[Oxalate]] | | ||
DiseasesDB = 31642 | | DiseasesDB = 31642 | | ||
ICD10 = | | ICD10 = {{ICD10|E|74|8|e|70}} | | ||
ICD9 = | | ICD9 = {{ICD9|271.8}} | | ||
ICDO = | | ICDO = | | ||
OMIM = | | OMIM = | | ||
Line 12: | Line 14: | ||
eMedicineSubj = med | | eMedicineSubj = med | | ||
eMedicineTopic = 3027 | | eMedicineTopic = 3027 | | ||
MeshID = | | MeshID = D006959 | | ||
}} | }} | ||
==Overview== | |||
'''Hyperoxaluria''' is an excessive urinary excretion of [[oxalate]]. Individuals with hyperoxaluria often have [[calcium oxalate]] [[kidney stone]]s. It is sometimes called '''Bird's disease''', after [[Golding Bird]], who first described the condition. | |||
== | ==Causes== | ||
Type I (PH1) is associated with [[AGXT]] protein, a key enzyme involved in breakdown of [[oxalate]]. PH1 is also an example of a protein mistargeting disease, wherein AGXT shows a trafficking defect: instead of being trafficked to [[peroxisome]]s, it is targeted to [[mitochondria]], where it is metabolically deficient despite being catalytically active. Type II is associated with [[GRHPR]].<ref name="urlPrimary hyperoxaluria - Genetics Home Reference">{{cite web |url=http://ghr.nlm.nih.gov/condition=primaryhyperoxaluria |title=Primary hyperoxaluria - Genetics Home Reference |format= |work= |accessdate=}}</ref> | |||
It is also a complication of [[jejunoileal bypass]], or in any patient who has lost much of the [[ileum]] with an intact [[Colon (anatomy)|colon]]. This is due to excessive absorption of oxalate from the colon.<ref>Surgery PreTest Self-Assessment and Review, Twelfth Edition</ref> | |||
== | ==Treatment== | ||
The main therapeutic approach to primary hyperoxaluria is still restricted to symptomatic treatment, i.e. [[kidney transplantation]] once the disease has already reached mature or terminal stages. However, through genomics and proteomics approaches, efforts are currently being made to elucidate the kinetics of AGXT folding which has a direct bearing on its targeting to appropriate subcellular localization. Secondary hyperoxaluria is much more common than primary hyperoxaluria, and should be treated by limiting dietary oxalate and providing calcium supplementation. A child with [[primary hyperoxaluria]] was treated with a liver and kidney transplant.<ref>[http://content.msn.co.in/News/National/NationalHT_090507_0902 India News & Business - MSN India: News, Business, Finance, Sports, Politics & more. - News<!-- Bot generated title -->]</ref> A favorable outcome is more likely if a kidney transplant is complemented by a liver transplant, given the disease originates in the liver. | |||
=== | ==Controversy== | ||
Perhaps the key difficulty in understanding pathogenesis of primary hyperoxaluria, or more specifically, why AGXT ends up in mitochondria instead of peroxisomes, stems from AGXT's somewhat peculiar evolution. Namely, prior to its current peroxysomal 'destiny', AGXT indeed used to be bound to mitochondria. AGXT's peroxisomal targeting sequence is uniquely specific for mammalian species, suggesting the presence of additional peroxisomal targeting information elsewhere in the AGT molecule. As AGXT was redirected to peroxisomes over the course of evolution, it is plausible that its current aberrant localization to mitochondria owes to some hidden molecular signature in AGXT's spatial configuration unmasked by PH1 mutations affecting the AGXT gene. <!--It is in this sense that we could conditionally understand PH1 as a sort of atavism acting on a molecular level. However, this should be taken as a metaphore with all the caveats of metaphoric thinking applied to science.--> | |||
== | ==Types== | ||
[[Idiopathic]] hyperoxaluria | * Primary hyperoxaluria | ||
* Enteric hyperoxaluria | |||
* [[Idiopathic]] hyperoxaluria | |||
* [[Oxalate]] poisoning | |||
=== | ==References== | ||
{{reflist}} | |||
[ | ==External links== | ||
* [http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=ph1 GeneReviews/NIH/NCBI/UW entry on Primary Hyperoxaluria Type 1] | |||
{{ | {{Inborn errors of carbohydrate metabolism}} | ||
{{ | {{Abnormal clinical and laboratory findings for urine}} | ||
{{DEFAULTSORT:Hyperoxaluria}} | |||
[[Category:Abnormal clinical and laboratory findings for urine]] | |||
[[Category:Inborn errors of carbohydrate metabolism]] |
Revision as of 18:53, 2 June 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Hyperoxaluria | |
Oxalate | |
ICD-10 | E74.8 |
ICD-9 | 271.8 |
DiseasesDB | 31642 |
eMedicine | med/3027 |
MeSH | D006959 |
Overview
Hyperoxaluria is an excessive urinary excretion of oxalate. Individuals with hyperoxaluria often have calcium oxalate kidney stones. It is sometimes called Bird's disease, after Golding Bird, who first described the condition.
Causes
Type I (PH1) is associated with AGXT protein, a key enzyme involved in breakdown of oxalate. PH1 is also an example of a protein mistargeting disease, wherein AGXT shows a trafficking defect: instead of being trafficked to peroxisomes, it is targeted to mitochondria, where it is metabolically deficient despite being catalytically active. Type II is associated with GRHPR.[1] It is also a complication of jejunoileal bypass, or in any patient who has lost much of the ileum with an intact colon. This is due to excessive absorption of oxalate from the colon.[2]
Treatment
The main therapeutic approach to primary hyperoxaluria is still restricted to symptomatic treatment, i.e. kidney transplantation once the disease has already reached mature or terminal stages. However, through genomics and proteomics approaches, efforts are currently being made to elucidate the kinetics of AGXT folding which has a direct bearing on its targeting to appropriate subcellular localization. Secondary hyperoxaluria is much more common than primary hyperoxaluria, and should be treated by limiting dietary oxalate and providing calcium supplementation. A child with primary hyperoxaluria was treated with a liver and kidney transplant.[3] A favorable outcome is more likely if a kidney transplant is complemented by a liver transplant, given the disease originates in the liver.
Controversy
Perhaps the key difficulty in understanding pathogenesis of primary hyperoxaluria, or more specifically, why AGXT ends up in mitochondria instead of peroxisomes, stems from AGXT's somewhat peculiar evolution. Namely, prior to its current peroxysomal 'destiny', AGXT indeed used to be bound to mitochondria. AGXT's peroxisomal targeting sequence is uniquely specific for mammalian species, suggesting the presence of additional peroxisomal targeting information elsewhere in the AGT molecule. As AGXT was redirected to peroxisomes over the course of evolution, it is plausible that its current aberrant localization to mitochondria owes to some hidden molecular signature in AGXT's spatial configuration unmasked by PH1 mutations affecting the AGXT gene.
Types
- Primary hyperoxaluria
- Enteric hyperoxaluria
- Idiopathic hyperoxaluria
- Oxalate poisoning
References
- ↑ "Primary hyperoxaluria - Genetics Home Reference".
- ↑ Surgery PreTest Self-Assessment and Review, Twelfth Edition
- ↑ India News & Business - MSN India: News, Business, Finance, Sports, Politics & more. - News